Evidence map›Paper›PMID 37088871›Full record

ReviewJournal of clinical laboratory analysis2023

Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.

Yifan Lin, Yongfu Shao, Jianing Yan, Guoliang Ye

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical laboratory analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Determination of Potential Inhibitors againstCurrent pharmaceutical design · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Towards EffectiveInternational journal of molecular sciences · 2025
    Review
  18. Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025
    Review
  19. Review
  20. Therapeutics and clinical risk management · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yifan LinDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Yongfu ShaoDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0001-6256-1426
Jianing YanDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0002-8781-9021
Guoliang YeDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0003-0600-9981
Ningbo University · CN

Funding

Affiliated Hospital of Medical School of Ningbo University Youth Talent Cultivation Program FYQMKY202001Key Scientific and Technological Projects of Ningbo 2021Z133Natural Science Foundation of Ningbo 202003N4198Youth Medical Backbone Talents Training Program of Ningbo
6 · The paper itself

Abstract

Increasing rates of Helicobacter pylori resistance are associated with multiple clinical challenges. Bacterial factors linked to H. pylori resistance are mutations, efflux pumps, and biofilms. Gene mutations such as nucleic acid synthesis-related gene mutations, rRNA coding gene mutations, and cell wall synthesis-related gene mutations are the most important mechanisms by which H. pylori evades bactericidal effects. These mechanisms are also closely related to the biological activity of the efflux pump systems and biofilms. Activation of the efflux pump system and biofilm formation both lead to the emergence of MDR strains, further increasing the difficulty of eradication therapy. In this review, the status of antibiotic resistance in H. pylori from different regions and countries is summarized and compared, and H. pylori resistance profiles and their changing trends in the clinic are described. Then, research progress on biomolecular mechanisms underlying antibiotic resistance, diagnostic methods, and treatment strategies are introduced and discussed. Challenges resulting from increasing resistance, potential solutions to combat increasing resistance, and future directions are discussed to help clinicians and researchers better address the emergence and spread of resistant H. pylori strains and optimize drug regimens. With the rate of H. pylori resistance to commonly used antibiotics increasing, more attention should be given to the selection of antibiotics and to monitoring resistance when antibiotics are used for clinical eradication treatment. Individualized precise eradication treatment under the guidance of drug susceptibility testing will become the mainstream method of treatment in the future.

Indexed as

Helicobacter InfectionsHelicobacter pyloriMycobacterium tuberculosisAnti-Bacterial AgentsClarithromycinDrug Resistance, BacterialHumansMetronidazoleMicrobial Sensitivity TestsAnti-Bacterial AgentsClarithromycinMetronidazoleantibiotic resistanceantimicrobial susceptibility testclarithromycinHelicobacter pylorimetronidazole

Identifiers

PMID37088871
PMCPMC10220298
OpenAlexW4366822743

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.